Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Abzena (United Kingdom) | Researchclopedia

Back to institutions

Abzena (United Kingdom)

Cambridgecompany

67

Works

8,485

Citations

56

h-index

Top Research Topics

Monoclonal and Polyclonal Antibodies Research HER2/EGFR in Cancer Research Biosimilars and Bioanalytical Methods

Top Researchers

Joshua Armenia AstraZeneca (United Kingdom)

313 works61,704 citationsh-index: 74

Recent Research

Abstract RF4-04: Mechanisms of resistance to capivasertib in combination with CDK4/6 inhibitor (CDK4/6i) plus fulvestrant in patients with hormone receptor-positive/HER2-negative (HR+/HER2−) advanced breast cancer (ABC): exploratory analysis from the Phase 1b CAPItello-292 study

D. R. Sudhan,C. Salinas-Souza,et al.

20261 citations

Click Chemistry and Applications

PARP inhibition in cancer therapy

Peptidase Inhibition and Analysis

vaccines and immunoinformatics approaches

T-cell and B-cell Immunology

Asthma and respiratory diseases

Cancer Immunotherapy and Biomarkers

Lung Cancer Treatments and Mutations

Immunotherapy and Immune Responses

Ultan McDermott AstraZeneca (United Kingdom)

513 works60,435 citationsh-index: 81

Mark J. O’Connor AstraZeneca (United Kingdom)

432 works21,308 citationsh-index: 69

Fábio Rossi University of Padua

367 works19,466 citationsh-index: 68

Dennis Wang Agency for Science, Technology and Research

289 works18,621 citationsh-index: 49

Andrew Menzies‐Gow AstraZeneca (United Kingdom)

366 works14,548 citationsh-index: 64

Abstract PD10-04: Visual functioning and characterization of visual effects from SERENA-6, a Phase 3 study of switch to camizestrant (CAMI) from aromatase inhibitor (AI) while continuing CDK4/6 inhibitor (CDK4/6i) at emergence of ESR1 mutations (ESR1m) during first-line therapy for patients (pts) with HR+/HER2− advanced breast cancer (ABC)

A Brufsky,F. C. Bidard,et al.

20260 citations

Abstract PS1-05-15: Trends in the Utilization of Prophylactic Anti-Emetic Therapy among Patients Initiating trastuzumab deruxtecan for Metastatic Breast Cancer in the United States

C. H. Shah,C. Nordon,et al.

20260 citations

T cell assays for non-clinical immunogenicity risk assessment: best practices recommended by the European Immunogenicity Platform

Sophie Tourdot,Anette Karle,et al.

20260 citations

Dendritic cell maturation assay for non-clinical immunogenicity risk assessment: best practices recommended by the European Immunogenicity Platform

Chloé Ackaert,Bruno Gonzalez-Nolasco,et al.

20251 citations

Deep Learning Predicts <i>EGFR</i> Mutation Status from Histology Images in Non–Small Cell Lung Cancer

Jongchan Park,Sangwon Shin,et al.

20251 citations